1.Research Progress of Indole in E.coli Biofilms on the Surface of Biomaterials
Danyan SU ; Wentian TANG ; Jinxu YANG ; Hua LIU ; Bangsheng LI ; Yingding ZHAO ; Yunchao HUANG
Journal of Kunming Medical University 2023;44(12):184-190
Escherichia coli is a highly adaptable opportunistic pathogen bacterium that can form biofilms on the surface of implants and generates persistent cells,leading to life-threatening infections that are difficult to treat with antibiotics alone.Therefore,there is a need for an effective E.coli biofilm inhibitor to combat this public health threat.Indole is a novel quorum-sensing signaling molecule of E.coli discovered in recent years,which is of great significance in regulating bacterial growth and biofilm formation,and is a potential target for future research on new anti-biofilm preparations.This article reviews the research progress on the formation of Escherichia coli biofilms,the microbial metabolism of indole and its regulation of Escherichia coli biofilm formation,in order to provide information for clinical treatment and drug development.
2.Recent Advances in Diagnosis and Treatment Strategies for Multiple Primary Lung Cancer.
Bangsheng LI ; Zhenghong YANG ; Yingding ZHAO ; Ying CHEN ; Yunchao HUANG
Chinese Journal of Lung Cancer 2023;26(11):863-873
As the utilization of computed tomography in lung cancer screening becomes more prevalent in the post-pandemic era, the incidence of multiple primary lung cancer (MPLC) has surged in various countries and regions. Despite the continued application of advanced histologic and sequencing technologies in this research field, the differentiation between MPLC and intrapulmonary metastasis (IM) remains challenging. In recent years, the specific mechanisms of genetic and environmental factors in MPLC have gradually come to light. Lobectomy still predominates in the treatment of MPLC, but the observation that tumor-specific sublobar resection has not detrimentally impacted survival appears to be a viable option. With the evolution of paradigms, the amalgamated treatment, primarily surgical, is an emerging trend. Among these, stereotactic ablative radiotherapy (SABR) and lung ablation techniques have emerged as efficacious treatments for early unresectable tumors and control of residual lesions. Furthermore, targeted therapies for driver-positive mutations and immunotherapy have demonstrated promising outcomes in the postoperative adjuvant phase. In this manuscript, we intend to provide an overview of the management of MPLC based on the latest discoveries.
.
Humans
;
Lung Neoplasms/therapy*
;
Early Detection of Cancer
;
Lung/surgery*
;
Treatment Outcome
;
Radiosurgery/methods*
;
Neoplasms, Multiple Primary/pathology*